Statistiques de base
| CIK | 1819113 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to LifeSci Acquisition II Corp
SEC Filings (Chronological Order)
Cette page fournit une liste complète et chronologique des documents déposés auprès de la SEC, à l'exclusion des documents relatifs à la participation que nous fournissons ailleurs.
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-39727 Science 37 Holdings, Inc. (Exact name of registrant as specified i |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* SCIENCE 37 HOLDINGS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 808644108 (CUSIP Number) Michael A. Boxer Senior Vice President and General Counsel Thermo Fisher Scientific Inc. 168 Third Avenue Walth |
|
| March 13, 2024 |
LSAQ / LifeSci Acquisition II Corp / Redmile Group, LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Science 37 Holdings, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 808644207 (CUSIP Number) Redmile Group, LLC Attn: Jennifer Ciresi One Letterman Drive, Bldg D, Ste D3-300 San Francisco, CA 94129 Attention: |
|
| March 12, 2024 |
As filed with the Securities and Exchange Commission on March 12, 2024 As filed with the Securities and Exchange Commission on March 12, 2024 Registration No. |
|
| March 12, 2024 |
Exhibit 99.(a)(5)(B) eMed completes tender offer for all outstanding shares of Science 37 March 12, 2024 — eMed, LLC (“eMed”) today announced the successful completion of the previously announced tender offer by its wholly-owned subsidiary, Marlin Merger Sub Corporation (“Purchaser”), for all the outstanding shares of common stock, par value $0.0001 per share, of Science 37 Holdings, Inc. (NASDAQ: |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) Science 37 Holdings, Inc. (Name of Subject Company) Science 37 Holdings, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 808644207 |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) SCIENCE 37 HOLDINGS, INC. (Name of Subject Company (Issuer)) MARLIN MERGER SUB CORPORATION a wholly-owned subsidiary of eMED, LLC (Name of Filing Persons (Offerors)) Common Stock, $0.0001 Par Value (Ti |
|
| March 12, 2024 |
As filed with the Securities and Exchange Commission on March 12, 2024 As filed with the Securities and Exchange Commission on March 12, 2024 Registration No. |
|
| March 12, 2024 |
SECOND AMENDED AND RESTATED BYLAWS SCIENCE 37 HOLDINGS, INC. (a Delaware corporation) ARTICLE I Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF SCIENCE 37 HOLDINGS, INC. (a Delaware corporation) ARTICLE I OFFICES SECTION 1. Registered Office. The registered office of Science 37 Holdings, Inc. (the “Corporation”) shall be established and maintained at the office of The Corporation Trust Company, in the City of Wilmington, in the County of New Castle, in the State of Delaware, and said compa |
|
| March 12, 2024 |
As filed with the Securities and Exchange Commission on March 12, 2024 As filed with the Securities and Exchange Commission on March 12, 2024 Registration No. |
|
| March 12, 2024 |
As filed with the Securities and Exchange Commission on March 12, 2024 As filed with the Securities and Exchange Commission on March 12, 2024 Registration No. |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39727 84-4278203 (Commissio |
|
| March 12, 2024 |
As filed with the Securities and Exchange Commission on March 12, 2024 As filed with the Securities and Exchange Commission on March 12, 2024 Registration No. |
|
| March 12, 2024 |
As filed with the Securities and Exchange Commission on March 12, 2024 As filed with the Securities and Exchange Commission on March 12, 2024 Registration No. |
|
| March 12, 2024 |
Exhibit (a)(5)(H) eMed completes tender offer for all outstanding shares of Science 37 March 12, 2024 — eMed, LLC (“eMed”) today announced the successful completion of the previously announced tender offer by its wholly-owned subsidiary, Marlin Merger Sub Corporation (“Purchaser”), for all the outstanding shares of common stock, par value $0. |
|
| March 12, 2024 |
Third Amended and Restated Certificate of Incorporation Science 37 Holdings, Inc. Exhibit 3.1 Third Amended and Restated Certificate of Incorporation of Science 37 Holdings, Inc. 1. The name of the corporation is “Science 37 Holdings, Inc.” (the “Corporation”). 2. The address of the Corporation’s registered office is The Corporation Trust Company, 1209 Orange Street, Wilmington 19801, in the County of New Castle. The Corporation Trust Company is the Corporation’s registered age |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) SCIENCE 37 HOLDINGS, INC. (Name of Subject Company (Issuer)) MARLIN MERGER SUB CORPORATION a wholly-owned subsidiary of eMED, LLC (Name of Filing Persons (Offerors)) Common Stock, $0.0001 Par Value (Ti |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Science 37 Holdings, Inc. (Name of Subject Company) Science 37 Holdings, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 808644207 |
|
| February 12, 2024 |
TABLE OF CONTENTS Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Science 37 Holdings, Inc. |
|
| February 12, 2024 |
eMed, LLC 990 Biscayne Blvd. Suite 1501 Miami, FL 33132 Exhibit (d)(3) eMed, LLC 990 Biscayne Blvd. Suite 1501 Miami, FL 33132 December 20, 2023 Confidential Science 37 Holdings, Inc. 800 Park Offices Drive Suite 3606 Research Triangle Park, NC 27709 Re: Proposed Transaction Ladies and Gentlemen: This letter agreement (this “Letter Agreement”) is entered into by (i) eMed, LLC (“eMed”), and (ii) Science 37 Holdings, Inc. (“Science 37”). Each of eMed and |
|
| February 12, 2024 |
Exhibit (a)(1)(B) Letter of Transmittal to Tender Shares of Common Stock of SCIENCE 37 HOLDINGS, INC. |
|
| February 12, 2024 |
Exhibit (d)(2) [SNCE LETTERHEAD] November 13, 2023 eMed LLC 990 Biscayne Blvd., Suite 1501 Miami, Florida 33132 Attention: Michael Cole, President and Chief Financial Officer Re: Confidentiality Agreement Ladies and Gentlemen: In connection with the consideration by eMed LLC, a Delaware limited liability company (“you” or “your”) of a possible negotiated acquisition of (a “Possible Transaction”) S |
|
| February 12, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Schedule TO-T (Rule 14d-100) SCIENCE 37 HOLDINGS, INC. |
|
| February 12, 2024 |
Exhibit (e)(2) [SNCE LETTERHEAD] November 13, 2023 eMed LLC 990 Biscayne Blvd. |
|
| February 12, 2024 |
SCIENCE 37 HOLDINGS, INC. Second Amended and Restated Executive Severance Policy Exhibit (e)(21) SCIENCE 37 HOLDINGS, INC. Second Amended and Restated Executive Severance Policy I. Overview The Executive Severance Policy (the “Policy”) established by Science 37 Holdings, Inc. (the “Company”) and approved by the Company’s Board of Directors, effective as of October 7, 2021, amended and restated as of April 18, 2023, is hereby amended and restated as set forth herein as the Poli |
|
| February 12, 2024 |
Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| February 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SCIENCE 37 HOLDINGS, INC. (Name of Subject Company (Issuer)) MARLIN MERGER SUB CORPORATION a wholly-owned subsidiary of eMED, LLC (Name of Filing Persons (Offerors)) Common Stock, $0.0001 Par Value (Title of Class of Se |
|
| February 12, 2024 |
eMed, LLC 990 Biscayne Blvd. Suite 1501 Miami, FL 33132 Exhibit (e)(3) eMed, LLC 990 Biscayne Blvd. Suite 1501 Miami, FL 33132 December 20, 2023 Confidential Science 37 Holdings, Inc. 800 Park Offices Drive Suite 3606 Research Triangle Park, NC 27709 Re: Proposed Transaction Ladies and Gentlemen: This letter agreement (this “Letter Agreement”) is entered into by (i) eMed, LLC (“eMed”), and (ii) Science 37 Holdings, Inc. (“Science 37”). Each of eMed and |
|
| February 12, 2024 |
Exhibit (a)(1)(C) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Science 37 Holdings, Inc. |
|
| February 12, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Science 37 Holdings, Inc. (Name of Subject Company) Science 37 Holdings, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 808644207 |
|
| February 12, 2024 |
Exhibit (a)(1)(D) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Science 37 Holdings, Inc. |
|
| February 12, 2024 |
Exhibit (e)(20) 12121 Bluff Creek Drive, Suite 100 Los Angeles, CA 90094 Phone: 984. |
|
| February 12, 2024 |
Exhibit (a)(1)(E) Notice of Guaranteed Delivery for Offer to Purchase for Cash All Outstanding Shares of Common Stock of Science 37 Holdings, Inc. |
|
| February 9, 2024 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 7, 2024 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commiss |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Science 37 Holdings, Inc. (Name of Subject Company) Science 37 Holdings, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 808644207 (CUSIP Number of |
|
| January 31, 2024 |
SC 13D/A 1 tm244726d1sc13da.htm SC 13D/A UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Science 37 Holdings, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 808644207 (CUSIP Number) Redmile Group, LLC Attn: Jennifer Ciresi One Letterman Drive, Bldg D, Ste |
|
| January 29, 2024 |
Exhibit 99.1 Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment Science 37 stockholders to receive $5.75 per share in cash Research Triangle Park, NC – January 29, 2024 – Science 37 Holdings, Inc. (Nasdaq: SNCE) (the “Company” or “Science 37”), the clinical research industry’s leading MetasiteTM, today announced that it has entered into a definitive merger |
|
| January 29, 2024 |
Exhibit 10.3 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of January 28, 2024, is by and among eMED, LLC, a Delaware limited liability company (“Parent”), Marlin Merger Sub Corporation, a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Pharmaceutical Product Development, LLC (the “Stockholder”). WHEREAS, as of the date |
|
| January 29, 2024 |
Exhibit 99.5 Employee FAQs 1. What was announced regarding Science 37 and eMed? ● We recently announced that Science 37 (also referred to as “we,” “us,” “our” or the “Company”) has entered into a definitive merger agreement with eMed at $5.75 per share, a premium to our existing share price. ○ The strategic merger aims to combine eMed’s extensive access to patients and patient engagement technolog |
|
| January 29, 2024 |
Exhibit 99.3 From: Science 37 To: Science 37 Customers Date: January 29, 2024 Subject: Science 37 Update: Access to More Patients and Faster Enrollment Dear [INSERT CUSTOMER NAME], Your success is top priority as we continue to enhance our ability to access new patients and accelerate enrollment on your behalf. Today, we’re pleased to announce that Science 37 has entered into a merger agreement wi |
|
| January 29, 2024 |
Exhibit 99.4 From: Science 37 To: Science 37 Vendors Date: January 29, 2024 Subject: Company Update: A New Chapter in Science 37’s Journey Dear [Partner’s Name], Today, we’re pleased to announce that Science 37 has entered into a merger agreement with eMed, the leader in on-demand virtual care and treatment for consumers. You can see a copy of the press release HERE. eMed brings an extensive patie |
|
| January 29, 2024 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among eMED, LLC MARLIN MERGER SUB CORPORATION and SCIENCE 37 HOLDINGS, Inc. Dated as of January 28, 2024 Table of Contents Page Article 1 THE OFFER AND THE MERGER 2 1.1 The Offer 2 1.2 Company Actions 5 1.3 The Merger 6 1.4 Closing and Effective Time of the Merger 7 Article 2 CONVERSION OF SECURITIES IN THE MERGER 7 2.1 Conversion of Securities 7 2.2 |
|
| January 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Science 37 Holdings, Inc. (Name of Subject Company (Issuer)) Marlin Merger Sub Corporation a wholly owned subsidiary of eMed, LLC (Names of Filing Persons (Offerors)) Common Stock, $0.0001 par value per share (Title of |
|
| January 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Science 37 Holdings, Inc. (Name of Subject Company) Science 37 Holdings, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 808644207 (CUSIP Number of |
|
| January 29, 2024 |
Exhibit 10.2 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of January 28, 2024, is by and among eMED, LLC, a Delaware limited liability company (“Parent”), Marlin Merger Sub Corporation, a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and the entities listed on Schedule I hereto (each, a “Stockholder”). WHEREAS, as of the |
|
| January 29, 2024 |
Exhibit 99.6 Customer FAQs 1. What was announced regarding Science 37 and eMed? ● We recently announced that Science 37 (also referred to as “we,” “us,” “our” or the “Company”) has entered into a definitive merger agreement with eMed at $5.75 per share, a premium to our existing share price. ○ The strategic merger aims to combine eMed’s extensive access to patients and patient engagement technolog |
|
| January 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 28, 2024 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commiss |
|
| January 29, 2024 |
Exhibit 99.1 Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment Science 37 stockholders to receive $5.75 per share in cash Research Triangle Park, NC – January 29, 2024 – Science 37 Holdings, Inc. (Nasdaq: SNCE) (the “Company” or “Science 37”), the clinical research industry’s leading MetasiteTM, today announced that it has entered into a definitive merger |
|
| January 29, 2024 |
Exhibit 10.1 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of January 28, 2024, is by and among eMED, LLC, a Delaware limited liability company (“Parent”), Marlin Merger Sub Corporation, a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and [●] (the “Stockholder”). WHEREAS, as of the date hereof, the Stockholder is the bene |
|
| January 29, 2024 |
Exhibit 10.4 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of January 28, 2024, is by and among eMED, LLC, a Delaware limited liability company (“Parent”), Marlin Merger Sub Corporation, a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and the entities listed on Schedule I hereto (each, a “Stockholder”). WHEREAS, as of the |
|
| January 29, 2024 |
Subject: Science 37 to merge with consumer virtual care company eMed Exhibit 99.2 Subject: Science 37 to merge with consumer virtual care company eMed Dear Squad, Today, we announced that Science 37 has entered into a merger agreement with eMed, the leader in on-demand virtual care and treatment for consumers. You can see a copy of the press release HERE. This strategic move is a positive step forward for Science 37 on our journey to transform clinical research whi |
|
| December 22, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 22, 2023 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commis |
|
| December 5, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SCIENCE 37 HOLDINGS, INC. Science 37 Holdings, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Science 37 Holdings, Inc. The Corporation was |
|
| December 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 5, 2023 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commiss |
|
| December 5, 2023 |
Science 37 Holdings, Inc. Announces 1-for-20 Reverse Stock Split effective December 8, 2023 Exhibit 99.1 NEWS RELEASE Science 37 Holdings, Inc. Announces 1-for-20 Reverse Stock Split effective December 8, 2023 RESEARCH TRIANGLE PARK, N.C., December 5, 2023—Science 37 Holdings, Inc. (Nasdaq: SNCE) (“Science 37” or the “Company”), the clinical research industry-leading Metasite™, announced today that it will effect a 1-for-20 reverse stock split (“Reverse Stock Split”) of its outstanding c |
|
| November 29, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 29, 2023 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commis |
|
| November 7, 2023 |
SCIENCE 37 HOLDINGS, INC. POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION SCIENCE 37 HOLDINGS, INC. POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION A. OVERVIEW In accordance with the applicable rules of The Nasdaq Stock Market (the “Nasdaq Rules”), Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Rule 10D-1 promulgated thereunder (“Rule 10D-1”), the Board of Directors (the “Board”) of Science 37 Holdings, Inc. (the “Com |
|
| November 7, 2023 |
Science 37 Reports Third Quarter 2023 Financial Results Exhibit 99.1 NEWS RELEASE Science 37 Reports Third Quarter 2023 Financial Results Research Triangle Park, N.C., November 7, 2023 — Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”), the industry-leading Metasite™, today reported its financial results for the quarter ended September 30, 2023. “Our third quarter results were highlighted by continued quarterly improvements in our key profitabi |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2023 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commiss |
|
| November 7, 2023 |
SCIENCE 37 HOLDINGS, INC. AMENDED AND RESTATED 2022 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN SCIENCE 37 HOLDINGS, INC. AMENDED AND RESTATED 2022 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan was established effective as of November 9, 2022, the date of its original approval by the Board, and was amended and restated as of November 1, 2023. The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who are expected to make import |
|
| November 7, 2023 |
SCIENCE 37 HOLDINGS, INC. 2021 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE SCIENCE 37 HOLDINGS, INC. 2021 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE Science 37 Holdings, Inc., a Delaware corporation (the “Company”), has granted to the participant listed below (“Participant”) the Restricted Stock Units (the “RSUs”) described in this Restricted Stock Unit Grant Notice (this “Grant Notice”), subject to the terms and conditions of the Science 37 Holdings, Inc. 2 |
|
| November 7, 2023 |
As filed with the Securities and Exchange Commission on November 7, 2023 As filed with the Securities and Exchange Commission on November 7, 2023 Registration No. |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 7, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) SCIENCE 37 HOLDINGS, INC. |
|
| October 27, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| October 3, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| August 8, 2023 |
Science 37 Reports Second Quarter 2023 Financial Results Exhibit 99.1 NEWS RELEASE Science 37 Reports Second Quarter 2023 Financial Results Research Triangle Park, N.C., August 8, 2023 — Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”), the industry-leading Metasite™, today reported its financial results for the quarter ended June 30, 2023. “The actions we have taken over the past nine months are leading to meaningful improvements as evidenced b |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2023 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commissio |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 27, 2023 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commission |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| May 15, 2023 |
Science 37 Holdings, Inc. Amended and Restated Executive Severance Policy EX-10.1+ 2 ex101amendedandrestatedexe.htm EX-10.1+ SCIENCE 37 HOLDINGS, INC. Amended and Restated Executive Severance Policy I.OVERVIEW The Executive Severance Policy (the “Policy”) established by Science 37 Holdings, Inc. (the “Company”) and approved by the Company’s Board of Directors, effective as of October 7, 2021 is hereby amended and restated as set forth herein as the Policy, effective as |
|
| May 15, 2023 |
Participation Agreement for the Amended and Restated Executive Severance Policy [Date] [Name] [Title] Re: Participation Agreement for Science 37 Holdings, Inc.’s Amended and Restated Executive Severance Plan Dear [Name], The Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Science 37 Holdings, Inc. (the “Company”) hereby extends to you (and with respect to the Company’s Chief Executive Officer, the Board hereby extends to you) the opportunit |
|
| May 15, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2023 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commission |
|
| May 15, 2023 |
Science 37 Reports First Quarter 2023 Financial Results Exhibit 99.1 NEWS RELEASE Science 37 Reports First Quarter 2023 Financial Results Research Triangle Park, N.C., May 15, 2023 — Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”), the industry-leading Metasite™, today reported its financial results for the quarter ended March 31, 2023. "First quarter results reflected continued progress with our key strategic initiatives,” stated David Coman, |
|
| May 11, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 11, 2023 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commission |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 3) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SCIENCE 37 HOLDINGS, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Stock Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 808644108 (CU |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 28, 2023 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commissio |
|
| April 19, 2023 |
SC TO-I/A 1 tm2310996d4sctoia.htm SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 2) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SCIENCE 37 HOLDINGS, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Stock Options to Purchase Common Stock, Par Value $0.0001 Per Share |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 13, 2023 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commissio |
|
| April 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 11, 2023 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commissio |
|
| April 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 1) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SCIENCE 37 HOLDINGS, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Stock Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 808644108 (CU |
|
| April 11, 2023 |
Exhibit 99.1 NEWS RELEASE Science 37 Unveils Three Global Centers of Excellence to Drive Efficiency, Speed and Quality Centers of Excellence to strengthen and scale the company’s Metasite offering and accelerate its path to profitability RESEARCH TRIANGLE PARK, N.C., April 11, 2023—Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading MetasiteTM, today unveiled three global Centers of Exc |
|
| April 3, 2023 |
Exhibit (a)(1)(K) Science 37 Holdings, Inc. Frequently Asked Questions About Offer to Exchange Eligible Options for Restricted Stock Units What is the Offer to Exchange Eligible Options for Restricted Stock Units? Since becoming public in October 2021, we have experienced a significant decline in our stock price. As a result, some of our employees and other service providers hold “underwater” stoc |
|
| April 3, 2023 |
Exhibit (a)(1)(D) FORM OF CONFIRMATION EMAIL TO ELIGIBLE PARTICIPANTS From: awardchoice@aon. |
|
| April 3, 2023 |
Exhibit (a)(1)(E) FORM OF REMINDER EMAIL Subject: Science 37 Holdings, Inc. – Exchange Offer Election Reminder To: Date: SCIENCE 37 HOLDINGS, INC. EXCHANGE OFFER Our records show you have not made an election to participate in Science 37 Holdings, Inc.’s Offer to Exchange Eligible Options for Restricted Stock Units (the “Exchange Offer”). This email is to remind you that April 28, 2023 at 11:59 p. |
|
| April 3, 2023 |
Informational Presentation to Eligible Participants. Stock Option Exchange Program April 3, 2023 Exhibit (a)(1)(I) Agenda • Stock Option Exchange Overview • Stock Option Eligibility • Exchange Details • Taxation Considerations • Example of Exchanges 2 Exchange Overview RSU refresher Stock Option Exchange Overview • Stock Options have been a key component of our long-term incentive program. |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SCIENCE 37 HOLDINGS, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Stock Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 808644108 (CUSIP Number of Clas |
|
| April 3, 2023 |
Exhibit 107 Calculation of Filing Fee Table Schedule TO-I (Form Type) Science 37 Holdings, Inc. |
|
| April 3, 2023 |
Screenshots from the Exchange Offer Website. Exhibit (a)(1)(H) |
|
| April 3, 2023 |
Form of Notice of Expiration of Exchange Offer Email. Exhibit (a)(1)(G) FORM OF NOTICE OF EXPIRATION OF EXCHANGE OFFER To: Eligible Participants Date: May 1, 2023 Subject: Expiration of Exchange Offer SCIENCE 37 HOLDINGS, INC. |
|
| April 3, 2023 |
Offer to Exchange Eligible Options for Restricted Stock Units, dated April 3, 2023. Exhibit (a)(1)(A) SCIENCE 37 HOLDINGS, INC. 800 PARK OFFICES DRIVE, SUITE 3606 RESEARCH TRIANGLE PARK, NORTH CAROLINA 27709 OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR RESTRICTED STOCK UNITS This document constitutes part of the prospectus relating to the securities that have been registered under the Securities Act of 1933, as amended. The prospectus relates to the 2015 Stock Plan and the 2021 Incenti |
|
| April 3, 2023 |
Election Form on the Exchange Offer Website. Exhibit (a)(1)(C) |
|
| April 3, 2023 |
Script of the Option Exchange Presentation to Eligible Participants. Exhibit (a)(1)(J) Speakers: Christine Pellizzari, Susan Eylward and Joe Fagan April 3, 2023 Exchange Offer Script (SLIDE 1) Hello, as you all know, I am Christine Pellizzari, Chief Legal and Human Resources Officer, and joining me today are Susan Eylward, Senior Corporate Counsel, and Joe Fagan our Director of Global Equity Compensation, and we are going to walk everyone through the stock option exchange offer. |
|
| April 3, 2023 |
Form of Option Agreement under 2015 Stock Plan. Exhibit (d)(2) Science 37, Inc. 2015 Stock Plan Notice Of Stock Option Grant (Installment Exercise) The Optionee has been granted the following option to purchase shares of the Common Stock of Science 37, Inc.: Name of Optionee: [] Total Number of Shares: [] Type of Option: [] Exercise Price per Share: $[] Date of Grant: [] Date Exercisable: [] Vesting Commencement Date: [] Expiration Date: []. Th |
|
| April 3, 2023 |
Exhibit (a)(1)(F) FORM OF FINAL REMINDER EMAIL Subject: Science 37 Holdings, Inc. – Exchange Offer Final Deadline To: Date: April 28, 2023 SCIENCE 37 HOLDINGS, INC. EXCHANGE OFFER This email is to remind you that today, April 28, 2023 at 11:59 p.m. Eastern Time is the final deadline to make an election to participate in Science 37 Holdings, Inc.’s Offer to Exchange Eligible Options for Restricted |
|
| April 3, 2023 |
Form of Announcement Email to Eligible Participants. Exhibit (a)(1)(B) FORM OF ANNOUNCEMENT EMAIL TO ELIGIBLE PARTICIPANTS Subject: Science 37 Holdings, Inc. |
|
| April 3, 2023 |
Form of Restricted Stock Unit Agreement under the 2021 Incentive Award Plan. Exhibit (a)(1)(L) SCIENCE 37 HOLDINGS, INC. 2021 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE Science 37 Holdings, Inc., a Delaware corporation (the “Company”), has granted to the participant listed below (“Participant”) the Restricted Stock Units (the “RSUs”) described in this Restricted Stock Unit Grant Notice (this “Grant Notice”), subject to the terms and conditions of the Science 3 |
|
| March 20, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2023 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commissio |
|
| March 10, 2023 |
March 10, 2023 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Science 37 Holdings, Inc. (the “Company”) Registration Statement on Form S-3 (File No. 333-270285) (the “Registration Statement”) Dear Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended (the “Securities Act”), th |
|
| March 9, 2023 |
Science 37 Holdings, Inc. 103,576,231 Shares of Common Stock 424B3 1 tm239025-1424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-260828 PROSPECTUS Science 37 Holdings, Inc. 103,576,231 Shares of Common Stock This prospectus relates to the offer and sale from time to time by the selling securityholders named in this prospectus (the “Selling Securityholders”) of up to 103,576,231 shares of common stock, par value $0.0001 per share (the “co |
|
| March 6, 2023 |
Exhibit 4.4 SCIENCE 37 HOLDINGS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20 Debt Securities Table Of Contents Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Se |
|
| March 6, 2023 |
Form of Option Agreement under 2022 Employment Inducement Incentive Award Plan [Signature Page to Stock Option Grant Notice] SCIENCE 37 HOLDINGS, INC. 2022 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Science 37 Holdings, Inc., a Delaware corporation (the “Company”) has granted to the participant listed below (“Participant”) the stock option (the “Option”) described in this Stock Option Grant Notice (this “Grant Notice”), subject to the terms and cond |
|
| March 6, 2023 |
Exhibit 21.1 Subsidiaries of Science 37 Holdings, Inc. Jurisdiction of Name of Subsidiary Organization Science 37, Inc. Delaware Diversity in Clinical Research Foundation Delaware Science 37 s.r.o Slovak Republic Science 37 UK Limited England and Wales |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39727 SCIENCE |
|
| March 6, 2023 |
2022 Employment Inducement Incentive Award Plan snce-2022inducementplan SCIENCE 37 HOLDINGS, INC. 2022 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities. Capitali |
|
| March 6, 2023 |
As filed with the Securities and Exchange Commission on March 6, 2023 As filed with the Securities and Exchange Commission on March 6, 2023 Registration No. |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 6, 2023 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commission |
|
| March 6, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Science 37 Holdings, Inc. |
|
| March 6, 2023 |
Form of Restricted Stock Unit Agreement under 2022 Employment Inducement Incentive Award Plan snce-formofrsuagreementi [Signature Page to Restricted Stock Unit Grant Notice] SCIENCE 37 HOLDINGS, INC. |
|
| March 6, 2023 |
Offer Letter by and between Science 37, Inc. and Darcy Forman, dated November 3, 2019. |
|
| March 6, 2023 |
Power of Attorney of Paul von Autenried Exhibit 24.2 POWER OF ATTORNEY The undersigned hereby constitutes and appoints David Coman and Mike Zaranek, and each of them singly (with full power to each of them to act alone), his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them, for him and in his name, place and stead, and in any and all capacities, to sign any and all amendmen |
|
| March 6, 2023 |
CORRESP 1 filename1.htm March 6, 2023 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Science 37 Holdings, Inc. – Registration Statement on Form S-3 Ladies and Gentlemen, Attached please find the Registration Statement on Form S-3 filed by Science 37 Holdings, Inc. (the “Company”) in connection with “shelf” r |
|
| March 6, 2023 |
Science 37 Reports Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 NEWS RELEASE Science 37 Reports Fourth Quarter and Full Year 2022 Financial Results Research Triangle Park, N.C., March 6, 2023 — Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”), the industry-leading Metasite™, today reported its financial results for the quarter and full year ended December 31, 2022. “Fourth quarter results demonstrated a healthy rebound in bookings and cont |
|
| March 6, 2023 |
As filed with the Securities and Exchange Commission on March 6, 2023 As filed with the Securities and Exchange Commission on March 6, 2023 Registration No. |
|
| December 30, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 27, 2022 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commis |
|
| December 30, 2022 |
424B3 1 a424b3no12filing.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-260828 Prospectus Supplement No. 12 (To Prospectus dated April 20, 2022) SCIENCE 37 HOLDINGS, INC. This Prospectus Supplement No. 12 (the “Prospectus Supplement”) updates, amends and supplements the prospectus of Science 37 Holdings Inc. (the “Company,” “we,” “us,” and “our”), dated April 20, 2022 (t |
|
| November 10, 2022 |
As filed with the Securities and Exchange Commission on November 10, 2022 ?As filed with the Securities and Exchange Commission on November 10, 2022 Registration No. |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 10, 2022 |
1 CONFIDENTIAL SEVERANCE AGREEMENT AND GENERAL RELEASE FOR EXECUTIVE LEVEL EMPLOYEES This Confidential Severance Agreement and General Release for Executive Level Employees (?Agreement?) is made by and between Steve Geffon (?Employee?) and Science 37, Inc. |
|
| November 10, 2022 |
Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan Exhibit?99.1 SCIENCE 37 HOLDINGS,?INC. 2022 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN ARTICLE?I. Purpose ? The Plan?s purpose is to enhance the Company?s ability to attract, retain and motivate persons who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities. Capitalized terms |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 10, 2022 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commis |
|
| November 10, 2022 |
Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-260828 Prospectus Supplement No. 11 (To Prospectus dated April 20, 2022) SCIENCE 37 HOLDINGS, INC. This Prospectus Supplement No. 11 (the "Prospectus Supplement") updates, amends and supplements the prospectus of Science 37 Holdings Inc. (the ?Company,? ?we,? ?us,? and ?our?), dated April 20, 2022 (the ?Prospectus?), which forms a par |
|
| November 10, 2022 |
Science 37 Reports Third Quarter 2022 Financial Results Exhibit 99.1 NEWS RELEASE Science 37 Reports Third Quarter 2022 Financial Results Research Triangle Park, N.C., November 10, 2022 ? Science 37 Holdings, Inc. (Nasdaq: SNCE), (?Science 37?) the Agile Clinical Trial Operating SystemTM, today reported its financial results for the quarter ended September 30, 2022. ?The third quarter was challenging from a bookings perspective as we experienced delays |
|
| November 10, 2022 |
Exhibit 107.1 Calculation of Filing Fee Tables S-8 (Form Type) SCIENCE 37 HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock reserved for |
|
| November 10, 2022 |
Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-260828 Prospectus Supplement No. 10 (To Prospectus dated April 20, 2022) SCIENCE 37 HOLDINGS, INC. This Prospectus Supplement No. 10 (the "Prospectus Supplement") updates, amends and supplements the prospectus of Science 37 Holdings Inc. (the ?Company,? ?we,? ?us,? and ?our?), dated April 20, 2022 (the ?Prospectus?), which forms a par |
|
| October 5, 2022 |
Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-260828 Prospectus Supplement No. 9 (To Prospectus dated April 20, 2022) SCIENCE 37 HOLDINGS, INC. This Prospectus Supplement No. 9 (the ?Prospectus Supplement?) updates, amends and supplements the prospectus of Science 37 Holdings Inc. (the ?Company,? ?we,? ?us,? and ?our?), dated April 20, 2022 (the ?Prospectus?), which forms a part |
|
| October 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 29, 2022 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commi |
|
| October 5, 2022 |
Exhibit 99.1 NEWS RELEASE Science 37 appoints Paul von Autenried to its Board of Directors Former Chief Information officer and Executive Committee member for Bristol Myers Squibb brings deep industry and technology expertise to Science 37. RESEARCH TRIANGLE PARK. October 5, 2022?Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System?, today announced the appointment o |
|
| September 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 30, 2022 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commi |
|
| September 30, 2022 |
Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-260828 Prospectus Supplement No. 8 (To Prospectus dated April 20, 2022) SCIENCE 37 HOLDINGS, INC. This Prospectus Supplement No. 8 (the “Prospectus Supplement”) updates, amends and supplements the prospectus of Science 37 Holdings Inc. (the “Company,” “we,” “us,” and “our”), dated April 20, 2022 (the “Prospectus”), which forms a part |
|
| September 12, 2022 |
Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-260828 Prospectus Supplement No. 7 (To Prospectus dated April 20, 2022) SCIENCE 37 HOLDINGS, INC. This Prospectus Supplement No. 7 (the ?Prospectus Supplement?) updates, amends and supplements the prospectus of Science 37 Holdings Inc. (the ?Company,? ?we,? ?us,? and ?our?), dated April 20, 2022 (the ?Prospectus?), which forms a part |
|
| September 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 9, 2022 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commis |
|
| September 12, 2022 |
Exhibit 99.1 NEWS RELEASE Science 37 Names Industry Veteran Michael Shipton as Chief Commercial Officer Shipton joins Science 37 to help capitalize on the high demand for decentralized clinical trials and drive further growth into enterprise opportunities. RESEARCH TRIANGLE PARK. September 12, 2022?Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System?, today announce |
|
| September 12, 2022 |
mployment Agreement, effective September 12, 2022, between Michael Shipton and Science 37, Inc. EXHIBIT 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the "Agreement') is entered into and effective as of September 12, 2022 (the "Effective Date"), by and between Michael Shipton (the "Executive") and Science 37, Inc. (the "Company"). Each of the Company and Executive are a "Party" and, collectively, they are the "Parties." RECITALS WHEREAS, the Company desires to empl |
|
| August 11, 2022 |
Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-260828 Prospectus Supplement No. 5 (To Prospectus dated April 20, 2022) SCIENCE 37 HOLDINGS, INC. This Prospectus Supplement No. 5 (the ?Prospectus Supplement?) updates, amends and supplements the prospectus of Science 37 Holdings Inc. (the ?Company,? ?we,? ?us,? and ?our?), dated April 20, 2022 (the ?Prospectus?), which forms a part |
|
| August 11, 2022 |
Science 37 Reports Second Quarter 2022 Financial Results Exhibit 99.1 NEWS RELEASE Science 37 Reports Second Quarter 2022 Financial Results Research Triangle Park, N.C., August 11, 2022 ? Science 37 Holdings, Inc. (Nasdaq: SNCE), (?Science 37?) the Agile Clinical Trial Operating SystemTM, today reported its financial results for the quarter ended June 30, 2022. "We made meaningful strides across our strategic priorities in the second quarter and our pat |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 11, 2022 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commissi |
|
| August 11, 2022 |
424B3 1 a06302022424b3prospectussu.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-260828 Prospectus Supplement No. 6 (To Prospectus dated April 20, 2022) SCIENCE 37 HOLDINGS, INC. This Prospectus Supplement No. 6 (the "Prospectus Supplement") updates, amends and supplements the prospectus of Science 37 Holdings Inc. (the “Company,” “we,” “us,” and “our”), dated April 20, |
|
| August 11, 2022 |
As filed with the Securities and Exchange Commission on August 11, 2022 S-8 1 tm2223086d2s8.htm FORM S-8 As filed with the Securities and Exchange Commission on August 11, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 Science 37 Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorpora |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| August 11, 2022 |
Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) SCIENCE 37 HOLDINGS, INC. |
|
| June 15, 2022 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto, the ?Schedule 13D?) relating to the common stock, $0.0001 par value per share, of Science 37 Holdings, |
|
| June 15, 2022 |
LSAQ / Lifesci Acquisition II Corp / Redmile Group, LLC - SC 13D/A Activist Investment SC 13D/A 1 tm2218489d1sc13da.htm SC 13D/A UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Science 37 Holdings, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 808644108 (CUSIP Number) Redmile Group, LLC Attn: Jennifer Ciresi One Letterman Drive, Bldg D, Ste |
|
| May 19, 2022 |
SCIENCE 37 HOLDINGS, INC. 103,576,231 Shares of Common Stock Prospectus Supplement No. 4 Filed Pursuant to Rule 424(b)(3) (to Prospectus dated April 20, 2022) Registration No. 333-260828 SCIENCE 37 HOLDINGS, INC. 103,576,231 Shares of Common Stock This Prospectus Supplement No. 4 (this ?prospectus supplement?) updates, amends and supplements the prospectus of Science 37 Holdings, Inc. (the ?Company,? ?we,? ?us,? and ?our?), dated April 20, 2022 (as previous |
|
| May 13, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 13, 2022 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commission |
|
| May 13, 2022 |
Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-260828 Prospectus Supplement No. 3 (To Prospectus dated April 20, 2022) SCIENCE 37 HOLDINGS, INC. This Prospectus Supplement No. 3 (the ?Prospectus Supplement?) updates, amends and supplements the prospectus of Science 37 Holdings Inc. (the ?Company,? ?we,? ?us,? and ?our?), dated April 20, 2022 (the ?Prospectus?), which forms a part |
|
| May 9, 2022 |
Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-260828 Prospectus Supplement No. 1 (To Prospectus dated April 20, 2022) SCIENCE 37 HOLDINGS, INC. This Prospectus Supplement No. 1 (the ?Prospectus Supplement?) updates, amends and supplements the prospectus of Science 37 Holdings Inc. (the ?Company,? ?we,? ?us,? and ?our?), dated April 20, 2022 (the ?Prospectus?), which forms a part |
|
| May 9, 2022 |
Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-260828 Prospectus Supplement No. 2 (To Prospectus dated April 20, 2022) SCIENCE 37 HOLDINGS, INC. This Prospectus Supplement No. 2 (the "Prospectus Supplement") updates, amends and supplements the prospectus of Science 37 Holdings Inc. (the ?Company,? ?we,? ?us,? and ?our?), dated April 20, 2022 (the ?Prospectus?), which forms a part |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2022 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commission F |
|
| May 9, 2022 |
Science 37 Reports First Quarter 2022 Financial Results Exhibit 99.1 NEWS RELEASE Science 37 Reports First Quarter 2022 Financial Results Research Triangle Park, N.C., May 9, 2022 ? Science 37 Holdings, Inc. (Nasdaq: SNCE), (?Science 37?) the Agile Clinical Trial Operating SystemTM, today reported its financial results for the quarter ended March 31, 2022. "The first quarter of 2022 was marked by continued execution across all of our strategic prioriti |
|
| May 4, 2022 |
Science 37 Holdings, Inc. 103,576,231 Shares of Common Stock TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(3)? ?Registration No. 333-260828? P R O S P E C T U S Science 37 Holdings, Inc. 103,576,231 Shares of Common Stock ? This prospectus relates to the offer and sale from time to time by the selling securityholders named in this prospectus (the ?Selling Securityholders?) of up to 103,576,231 shares of common stock, par value $0.0001 per share, consisti |
|
| April 27, 2022 |
Subject to Completion, dated April 8, 2022 TABLE OF CONTENTS The information in this prospectus is not complete and may be changed. |
|
| April 8, 2022 |
As filed with the Securities and Exchange Commission on April 8, 2022 Table of Contents As filed with the Securities and Exchange Commission on April 8, 2022 Registration No. |
|
| April 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Science 37 Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 808644108 (CUSIP Number) Peter Hebert Lux Capital Management, LLC 920 Broadway, 11th Floor New York, NY 10010 (646) 475-4385 (Name, Addres |
|
| March 23, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 22, 2022 |
Exhibit 21.1 Subsidiaries of Science 37 Holdings, Inc. Jurisdiction of Name of Subsidiary Organization Science 37, Inc. Delaware Diversity in Clinical Research Foundation Delaware Science 37 s.r.o Slovak Republic Science 37 Switzerland GmbH Switzerland Science 37 UK Limited England and Wales |
|
| March 22, 2022 |
Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-260828 Prospectus Supplement No. 1 (To Prospectus dated January 25, 2022) SCIENCE 37 HOLDINGS, INC. This Prospectus Supplement No. 1 updates, amends and supplements the prospectus of Science 37 Holdings Inc. (the ?Company,? ?we,? ?us,? and ?our?), dated January 25, 2022 (the ?Prospectus?), which forms a part of our Registration Statem |
|
| March 22, 2022 |
Employment Agreement by and between Science 37, Inc. and Christine Pellizzari, dated June 7, 2021. |
|
| March 22, 2022 |
Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-260828 Prospectus Supplement No. 2 (To Prospectus dated January 25, 2022) SCIENCE 37 HOLDINGS, INC. This Prospectus Supplement No. 2 updates, amends and supplements the prospectus of Science 37 Holdings Inc. (the ?Company,? ?we,? ?us,? and ?our?), dated January 25, 2022 (the ?Prospectus?), which forms a part of our Registration Statem |
|
| March 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 22, 2022 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commissio |
|
| March 22, 2022 |
As filed with the Securities and Exchange Commission on March 22, 2022 ? As filed with the Securities and Exchange Commission on March 22, 2022 Registration No. |
|
| March 22, 2022 |
Science 37 Holdings, Inc. Executive Severance Policy Exhibit 10.21 SCIENCE 37 HOLDINGS, INC. Executive Severance Policy I.OVERVIEW This Executive Severance Policy (the ?Policy?) has been established by Science 37 Holdings, Inc. (the ?Company?), effective as of October 7, 2021 (the ?Effective Date?). This Policy is an ?employee welfare benefit plan? (as defined in Section 3(1) of ERISA) and a ?top hat? welfare plan for a select group of management or |
|
| March 22, 2022 |
Science 37 Reports Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 NEWS RELEASE Science 37 Reports Fourth Quarter and Full Year 2021 Financial Results Research Triangle Park, N.C., March 22, 2022 ? Science 37 Holdings, Inc. (Nasdaq: SNCE), (?Science 37?) the Agile Clinical Trial Operating SystemTM, today reported its financial results for the quarter and full year ended December 31, 2021. ?Our impressive financial performance in the fourth quarter an |
|
| March 22, 2022 |
Exhibit 4.1 DESCRIPTION OF REGISTERED SECURITIES General The following description summarizes some of the terms of our Second Amended and Restated Certificate of Incorporation (the ?certificate of incorporation?) and the Amended and Restated Bylaws (the ?bylaws?) of Science 37 Holdings, Inc. and its subsidiaries (the ?Company,? ?we,? ?us,? and ?our?) and of the General Corporation Law of the State |
|
| March 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39727 SCIENCE |
|
| February 14, 2022 |
JOINT FILING AGREEMENT February 14, 2022 EXHIBIT 99.1 JOINT FILING AGREEMENT February 14, 2022 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the ?Act?), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule or regulation thereunder (including a |
|
| February 14, 2022 |
LSAQ / Lifesci Acquisition II Corp / Ikarian Capital, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Science 37 Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 808644108 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Science 37 Holdings, Inc. (formerly known as Lifesci Acquisition II Corp.) (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 808644108 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Ch |
|
| February 10, 2022 |
Science 37 Holdings, Inc. 103,576,231 Shares of Common Stock TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(3)? ?Registration No. 333-260828? P R O S P E C T U S Science 37 Holdings, Inc. 103,576,231 Shares of Common Stock ? This prospectus relates to the offer and sale from time to time by the selling securityholders named in this prospectus (the ?Selling Securityholders?) of up to 103,576,231 shares of common stock, par value $0.0001 per share, consisti |
|
| February 10, 2022 |
As filed with the Securities and Exchange Commission on February 9, 2022 ?As filed with the Securities and Exchange Commission on February 9, 2022 Registration No. |
|
| February 10, 2022 |
Exhibit 99.3 Science 37, Inc. 2015 Stock Plan Adopted on September 8, 2015 TABLE OF CONTENTS Page SECTION 1. ESTABLISHMENT AND PURPOSE 1 SECTION 2. ADMINISTRATION 1 (a) Committees of the Board of Directors 1 (b) Authority of the Board of Directors 1 SECTION 3. ELIGIBILITY 1 (a) General Rule 1 (b) Ten-Percent Stockholders 1 SECTION 4. STOCK SUBJECT TO PLAN 2 (a) Basic Limitation 2 (b) Additional Sh |
|
| February 10, 2022 |
Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) SCIENCE 37 HOLDINGS, INC. |
|
| February 10, 2022 |
Exhibit 99.1 SCIENCE 37 HOLDINGS, INC. 2021 INCENTIVE AWARD PLAN ARTICLE I. Purpose The Plan?s purpose is to enhance the Company?s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities. Capitalized terms used in the P |
|
| February 10, 2022 |
Science 37 Holdings, Inc. 2021 Employee Stock Purchase Plan. Exhibit 99.2 SCIENCE 37 HOLDINGS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN Article I. PURPOSE The purpose of this Plan is to assist Eligible Employees of the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company. The Plan consists of two components: (i) the Section 423 Component and (ii) the Non-Section 423 Component. The Section 423 Component is intended to |
|
| January 21, 2022 |
CORRESP 1 filename1.htm January 21, 2022 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Science 37 Holdings, Inc. Registration Statement on Form S-1 Filed November 5, 2021 Registration No. 333-260828 Ladies and Gentlemen: In accordance with Rule 461 of Regulation C of the General Rules and Regula |
|
| January 20, 2022 |
As filed with the Securities and Exchange Commission on January 20, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 20, 2022 Registration No. |
|
| December 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 2 x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39727 SCIENCE 37 HOLDIN |
|
| December 27, 2021 |
As filed with the Securities and Exchange Commission on December 23, 2021 Table of Contents As filed with the Securities and Exchange Commission on December 23, 2021 Registration No. |
|
| December 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 20, 2021 Science 37 Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commis |
|
| December 20, 2021 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K)(1) Exhibit A JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K)(1) The undersigned acknowledge and agree that the Statement on Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the shares of Common Stock, par value $0. |
|
| December 20, 2021 |
LSAQ / Lifesci Acquisition II Corp / Thermo Fisher Scientific Inc. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* SCIENCE 37 HOLDINGS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 808644108 (CUSIP Number) Michael A. Boxer Senior Vice President, General Counsel and Secretary Thermo Fisher Scientific Inc. 168 Third Aven |
|
| November 15, 2021 |
Management’s Discussion and Analysis of Financial Condition and Results of Operations Exhibit 99.4 Management?s Discussion and Analysis of Financial Condition and Results of Operations You should read the following discussion and analysis of the Company?s financial condition and results of operations together with the ?Selected Historical Consolidated Financial Data? section of this proxy statement/prospectus and the Company?s audited consolidated financial statements and unaudited |
|
| November 15, 2021 |
Exhibit 10.18 SPONSOR LOCK-UP AGREEMENT THIS SPONSOR LOCK-UP AGREEMENT (this ?Agreement?) is dated as of May 6, 2021, by and between the undersigned (the ?Holder?) and LifeSci Acquisition II Corp., a Delaware corporation (?Parent?). Capitalized terms used and not otherwise defined herein shall have the meanings given such terms in the Merger Agreement (as defined below). BACKGROUND A. Parent, Life |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 6, 2021 Science 37 Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incor |
|
| November 15, 2021 |
Science 37, Inc. Condensed Consolidated Balance Sheets Exhibit 99.3 Condensed consolidated financial statements (unaudited) Science 37, Inc. For the Three and Nine Months Ended September 30, 2021 and 2020 Science 37, Inc. Condensed Consolidated Balance Sheets (unaudited) September 30, 2021 December 31, 2020 Assets Current assets: Cash and cash equivalents $ 7,996,362 $ 32,478,948 Restricted cash - 1,004,142 Accounts receivable, net (including amounts |
|
| November 15, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 15, 2021 |
Science 37 Holders Support Agreement Exhibit 10.19 May 6, 2021 LifeSci Acquisition II Corp. 250 W. 55th St., #3401 New York, NY 10019 Attention: Andrew McDonald Re: Support Agreement Ladies and Gentlemen: This letter (this ?Support Agreement?) is being delivered by each of those stockholders of Science 37, Inc., a Delaware corporation (the ?Company?), whose names appear on the signature pages of this Agreement (each, a ?Stockholder? |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 15, 2021 Science 37 Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commis |
|
| November 15, 2021 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Defined terms included below have the same meaning as terms defined and included elsewhere in Current Report on Form 8-K. The following unaudited pro forma condensed combined financial statements present the combination of the financial information of LSAQ and Science 37, adjusted to give effect to the Business Combination. |
|
| November 15, 2021 |
Warrant Exchange Agreement between LSAQ and the Sponsor. Exhibit 4.3 WARRANT EXCHANGE AGREEMENT This WARRANT EXCHANGE AGREEMENT dated as of October 6, 2021, is by and between LifeSci Acquisition II Corp. a Delaware corporation (the ?Company?) LifeSci Holdings LLC, a Delaware limited liability company (?Holder?). WHEREAS, on November 24, 2020, the Company entered into a Private Warrant Agreement (the ?Warrant Agreement?) by and between the Company and th |
|
| November 15, 2021 |
Science 37 Reports Quarterly Financial Results for the Period Ended September 30, 2021 Exhibit 99.1 NEWS RELEASE Science 37 Reports Quarterly Financial Results for the Period Ended September 30, 2021 LOS ANGELES, November 15, 2021 ? Science 37 Holdings, Inc. (Nasdaq: SNCE), (?Science 37?) the Operating System for today?s more agile clinical trials, today reported its financial results for the quarter ended September 30, 2021. ?We are pleased to have delivered another quarter of stro |
|
| November 8, 2021 |
LSAQ / Lifesci Acquisition II Corp / PPD, Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* SCIENCE 37 HOLDINGS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 808644108 (CUSIP Number) Julia James PPD, Inc. 929 North Front Street Wilmington, North Carolina 28401 (910) 251-0081 (Name, Address and T |
|
| November 5, 2021 |
Exhibit 10.17 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT ? THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is entered into as of the 6th day of October, 2021, by and among Science 37 Holdings, Inc., a Delaware corporation (f/k/a LifeSci Acquisition II Corp.) (the ?Company?), the equityholders designated as Sponsor Equityholders on Schedule A hereto (collectively, |
|
| November 5, 2021 |
2021 Science 37 Holdings, Inc. Incentive Award Plan. Exhibit 10.13 SCIENCE 37 HOLDINGS, INC. 2021 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan?s purpose is to enhance the Company?s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities. Capitalized terms used in the |
|
| November 5, 2021 |
2021 Science 37 Holdings, Inc. Employee Stock Purchase Plan. Exhibit 10.16 SCIENCE 37 HOLDINGS, INC. ? 2021 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE The purpose of this Plan is to assist Eligible Employees of the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company. The Plan consists of two components: (i) the Section 423 Component and (ii) the Non-Section 423 Component. The Section 423 Component is intended |
|
| November 5, 2021 |
As filed with the Securities and Exchange Commission on November 5, 2021 Table of Contents ? As filed with the Securities and Exchange Commission on November 5, 2021 Registration No. |
|
| November 5, 2021 |
Amended and Restated Certificate of Incorporation. Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LIFESCI ACQUISITION II CORP. ? LifeSci Acquisition II Corp. (the ?Corporation?), a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify as follows: 1.The name of the Corporation is LifeSci Acquisition II Corp. The Corporation was incorporated under the |
|
| November 5, 2021 |
Exhibit 10.20 ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? DIRECTOR NOMINATION AGREEMENT ? BY AND AMONG ? LIFESCI ACQUISITION II CORP., ? LIFESCI HOLDINGS LLC, ? SCIENCE 37, INC. ? AND ? THE STOCKHOLDERS PARTY HERETO ? Dated as of October 6, 2021 ? ? ? CONTENTS ? ? ? ? ? Page Article I. DEFINITIONS AND CONSTRUCTION 1 Section 1.01 Definitions 1 Section 1.02 Rules of Construction 4 Article II. CORPORATE GO |
|
| October 18, 2021 |
Exhibit B Execution Version DIRECTOR NOMINATION AGREEMENT BY AND AMONG LIFESCI ACQUISITION II CORP. |
|
| October 18, 2021 |
LSAQ / Lifesci Acquisition II Corp / Lux Capital Management, LLC - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Science 37 Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 808644108 (CUSIP Number) Peter Hebert Lux Capital Management, LLC 920 Broadway, 11th Floor New York, NY 10010 (646) 475-4385 (Name, Address and Telephone Num |
|
| October 18, 2021 |
Exhibit 1 JOINT FILING AGREEMENT This Agreement will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock of Science 37 Holdings, Inc. |
|
| October 18, 2021 |
Joint Filing Agreement by and among the Reporting Persons. Exhibit A JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K)(1) The undersigned acknowledge and agree that the Statement on Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the shares of Common Stock, par value $0. |
|
| October 18, 2021 |
LSAQ / Lifesci Acquisition II Corp / Redmile Group, LLC - SC 13D Activist Investment UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Science 37 Holdings, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 808644108 (CUSIP Number) Redmile Group, LLC Jeremy C. Green One Letterman Drive, Bldg D, Ste D3-300 San Francisco, CA 94129 Attention: Legal |
|
| October 18, 2021 |
LSAQ / Lifesci Acquisition II Corp / PPD, Inc. - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* SCIENCE 37 HOLDINGS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 808644108 (CUSIP Number) Julia James PPD, Inc. 929 North Front Street Wilmington, North Carolina 28401 (910) 251-0081 (Name, Address |
|
| October 18, 2021 |
EX-99.C 4 d244495dex99c.htm EX-C Exhibit C Execution Version AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into as of the 6th day of October, 2021, by and among Science 37 Holdings, Inc., a Delaware corporation (f/k/a LifeSci Acquisition II Corp.) (the “Company”), the equityholders designated as Sponsor Equi |
|
| October 18, 2021 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto, the ?Schedule 13D?) relating to the common stock, $0.0001 par value per share, of Science 37 Holdings, |
|
| October 15, 2021 |
EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the common stock, $0. |
|
| October 15, 2021 |
LSAQ / Lifesci Acquisition II Corp / LifeSci Holdings LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 Science 37 Holdings, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 808644108 (CUSIP Number) October 6, 2021 (Date of Event |
|
| October 13, 2021 |
Amended and Restated Bylaws of Science 37 Holdings, Inc. Exhibit 3.3 Amended and Restated Bylaws of Science 37 Holdings, Inc. (a Delaware corporation) Table of Contents Page Article I - Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article II - Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Business to be Brought before a Meeting. 2 2.5 Notice of Nominations for Election to t |
|
| October 13, 2021 |
Specimen Stock Certificate of Science 37 Holdings, Inc. Exhibit 4.1 NUMBER C- SHARES SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP Science 37 Holdings, Inc. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE This Certifies that is the owner of FULLY PAID AND NON-ASSESSABLE SHARES OF THE PAR VALUE OF $0.0001 EACH OF THE COMMON STOCK OF Science 37 Holdings, Inc. (THE ?COMPANY?) transferable on the books of the Company in person or by duly authorized attorn |
|
| October 13, 2021 |
Form of Option Agreement under 2021 Science 37 Holdings, Inc. Incentive Award Plan. Exhibit 10.14 SCIENCE 37 HOLDINGS, INC. 2021 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Science 37 Holdings, Inc., a Delaware corporation (the ?Company?) has granted to the participant listed below (?Participant?) the stock option (the ?Option?) described in this Stock Option Grant Notice (this ?Grant Notice?), subject to the terms and conditions of the Science 37 Holdings, Inc. 2021 Incentive |
|
| October 13, 2021 |
Exhibit 99.1 Science 37, the Operating System for Agile Clinical Trials, Closes Business Combination with LifeSci Acquisition II Corp. and Will Begin Trading on Nasdaq as SNCE ? Science 37 to debut on Nasdaq as a publicly traded company under ticker symbol ?SNCE? ? Business combination will provide Science 37 with approximately $235 million in cash proceeds to support continued growth ? Science 37 |
|
| October 13, 2021 |
Form of Restricted Stock Unit Agreement under 2021 Science 37 Holdings, Inc. Incentive Award Plan. Exhibit 10.15 SCIENCE 37 HOLDINGS, INC. 2021 INCENTIVE AWARD PLAN RESTRICTED STOCK Unit Grant Notice Science 37 Holdings, Inc., a Delaware corporation (the ?Company?), has granted to the participant listed below (?Participant?) the Restricted Stock Units (the ?RSUs?) described in this Restricted Stock Unit Grant Notice (this ?Grant Notice?), subject to the terms and conditions of the Science 37 Ho |
|
| October 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 6, 2021 Science 37 Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commissi |
|
| October 13, 2021 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Defined terms included below have the same meaning as terms defined and included elsewhere in Current Report on Form 8-K. The following unaudited pro forma condensed combined financial statements present the combination of the financial information of LSAQ and Science 37, adjusted to give effect to the Business Combination. |
|
| October 13, 2021 |
Exhibit 21.1 Subsidiaries of Science 37 Holdings, Inc. Jurisdiction of Name of Subsidiary Organization Science 37 s.r.o Slovak Republic Science 37 Switzerland GmbH Switzerland |
|
| October 13, 2021 |
Exhibit 16.1 October 13, 2021 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 United States of America Commissioners: We have read the statements of Science 37 Holdings, Inc. (formerly known as LifeSci Acquisition II Corp.) included under Item 4.01 of its Form 8-K dated October 13, 2021. We agree with the statements concerning our Firm under |
|
| October 13, 2021 |
Amended and Restated By-Laws of LifeSci Acquisition II Corp. Exhibit 3.2 Amended and Restated Bylaws of LIFESCI ACQUISITION II CORP. (a Delaware corporation) Table of Contents Page Article I - Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article II - Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Business to be Brought before a Meeting. 2 2.5 Notice of Nominations for Election t |
|
| October 6, 2021 |
Regulation FD Disclosure, Submission of Matters to a Vote of Security Holders United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 4, 2021 Date of Report (Date of earliest event reported) LifeSci Acquisition II Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39727 84-4278203 (State or other jurisdiction of incorporation) (Commis |
|
| September 24, 2021 |
PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT TABLE OF CONTENTS ? Filed Pursuant to Rule 424(b)(3)? ?Registration No. 333-258205? PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT Dear Stockholders: You are cordially invited to attend the special meeting of the stockholders (the ?Meeting?) of LifeSci Acquisition II Corp. (?LSAQ?), which will be held at 10:00 a.m., Eastern Time, on October 4, 2021. The Meeting will be held via teleconference using t |
|
| September 21, 2021 |
LifeSci Acquisition II Corp. 250 W. 55th St., #3401 New York, New York 10019 LifeSci Acquisition II Corp. 250 W. 55th St., #3401 New York, New York 10019 September 21, 2021 VIA EDGAR & TELECOPY Scott Anderegg Jennifer L?pez-Molina Division of Corporation Finance Office of Trade & Services U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 RE: Lifesci Acquisition II Corp. (the ?Company?) Registration Statement on Form S-4 (File No. 333-258205) |
|
| September 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* LifeSci Acquisition II Corp (Name of Issuer) Common Stock (Title of Class of Securities) 53229E103 (CUSIP Number) May 10, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| September 15, 2021 |
Amended and Restated Certificate of Incorporation. TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on September 15, 2021. Registration No. 333-258205? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? AMENDMENT NO. 2 to Form S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ? LIFESCI ACQUISITION II CORP. (Exact name of registrant as specified in its charter) ? ? Delaware (State or o |
|
| August 31, 2021 |
Consent of Emily Rollins to be named as a director. Exhibit 99.7 Consent to be Named as a Director Nominee In connection with the filing by LifeSci Acquisition II Corp. of the Registration Statement on Form S-4 (the ?Registration Statement?) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the |
|
| August 31, 2021 |
Form of Indemnification Agreement. EXHIBIT 10.8 INDEMNIFICATION And Advancement AGREEMENT This Indemnification and Advancement Agreement (as amended or amended and restated, this ?Agreement?) is made as of [ l ], 2021 (the ?Effective Date?) by and between Science 37 Holdings, Inc., a Delaware corporation (the ?Company?), and , [ l ] of the Company (?Indemnitee?). RECITALS: WHEREAS, the Board of Directors of the Company (the ?Board? |
|
| August 31, 2021 |
Form of Warrant Exchange Agreement between LSAQ and the Sponsor. Exhibit 4.3 WARRANT EXCHANGE AGREEMENT This WARRANT EXCHANGE AGREEMENT dated as of , 2021, is by and between LifeSci Acquisition II Corp., a Delaware corporation (the “Company”) and LifeSci Holdings LLC, a Delaware limited liability company (“Holder”). WHEREAS, on November 24, 2020, the Company entered into a Private Warrant Agreement (the “Warrant Agreement”) by and between the Company and the Ho |
|
| August 31, 2021 |
As filed with the U.S. Securities and Exchange Commission on August 31, 2021. TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on August 31, 2021. Registration No. 333-258205? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? AMENDMENT NO. 1 to Form S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ? LIFESCI ACQUISITION II CORP. (Exact name of registrant as specified in its charter) ? ? Delaware (State or othe |
|
| August 31, 2021 |
Exhibit 99.8 YOUR VOTE IS IMPORTANT. PLEASE VOTE TODAY. SPECIAL MEETING OF STOCKHOLDERS , 2021 This Proxy is Solicited On Behalf Of The Board Of Directors Vote Your Proxy by mail: Mark, sign and date your proxy card and return it in the postage-paid envelope provided. ?FOLD HERE ? DO NOT SEPARATE ? INSERT IN ENVELOPE PROVIDED ? THE BOARD OF DIRECTORS RECOMMENDS A VOTE ?FOR? PROPOSAL NOS. 1, 2, 3 ( |
|
| August 31, 2021 |
Exhibit 21.1 List of Subsidiaries of LifeSci Acquisition II Corp. Name of Subsidiary Jurisdiction of Organization LifeSci Acquisition II Merger Sub, Inc. Delaware List of Subsidiaries of Science 37, Inc. Name of Subsidiary Jurisdiction of Organization Science 37 s.r.o Slovak Republic Science 37 Switzerland GmbH Switzerland |
|
| August 31, 2021 |
Scott Anderegg Jennifer L?pez-Molina August 31, 2021 Page 1 Via Edgar August 31, 2021 Scott Anderegg Jennifer L?pez-Molina Division of Corporation Finance Office of Trade & Services U. |
|
| August 27, 2021 |
Exhibit 21.1 List of Subsidiaries of LifeSci Acquisition II Corp. LifeSci Acquisition II Merger Sub, Inc., a Delaware corporation |
|
| August 27, 2021 |
Exhibit 4.3 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of June 30, 2021, the end of the period covered by this Annual Report on Form 10-K, Lifesci Acquisition II Corp. (the ?Company,? ?we,? ?us,? or ?our?) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange |
|
| August 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39727 LIFESCI ACQUISITION II CORP. (Exact |
|
| July 28, 2021 |
Power of Attorney (included on the signature page hereto). TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on July 27, 2021. Registration No. 333-???????? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? Form S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ? LIFESCI ACQUISITION II CORP. (Exact name of registrant as specified in its charter) ? ? Delaware (State or other jurisdiction of in |
|
| July 28, 2021 |
Consent of John W. Hubbard to be named as a director. EX-99.2 8 tm2118980d6ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Consent to be Named as a Director Nominee In connection with the filing by LifeSci Acquisition II Corp. of the Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securi |
|
| July 28, 2021 |
Consent of Neil Tiwari to be named as a director. Exhibit 99.6 Consent to be Named as a Director Nominee In connection with the filing by LifeSci Acquisition II Corp. of the Registration Statement on Form S-4 (the ?Registration Statement?) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the |
|
| July 28, 2021 |
Consent of Adam Goulburn to be named as a director. Exhibit 99.4 Consent to be Named as a Director Nominee In connection with the filing by LifeSci Acquisition II Corp. of the Registration Statement on Form S-4 (the ?Registration Statement?) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the |
|
| July 28, 2021 |
Offer Letter by and between Science 37, Inc. and Stephen Geffon, dated November 13, 2019. Exhibit 10.16 Steve Geffon November 13, 2019 12121 Bluff Creek Drive, Suite 100 Los Angeles, CA 90094 Phone: 984377.3737 Fax: 888.534.6531 November 13, 2019 Steve Geffon Re: Offer of Employment Dear Steve: On behalf of Science 37, Inc. ("Science 37"), I am pleased to offer you employment in the position of Chief Commercial Officer (CCO), reporting to Science 37's Chief Executive Officer. This lett |
|
| July 28, 2021 |
Consent of Robert Faulkner to be named as a director. Exhibit 99.3 Consent to be Named as a Director Nominee In connection with the filing by LifeSci Acquisition II Corp. of the Registration Statement on Form S-4 (the ?Registration Statement?) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the |
|
| July 28, 2021 |
Consent of David Coman to be named as a director. Exhibit 99.1 Consent to be Named as a Director Nominee In connection with the filing by LifeSci Acquisition II Corp. of the Registration Statement on Form S-4 (the ?Registration Statement?) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the |
|
| July 28, 2021 |
Offer Letter by and between Science 37, Inc. and Jonathan Cotliar, dated October 20, 2016. Exhibit 10.17 5875 Green Valley Circle, Suite 100 Culver City, CA 90230 Phone: 984.377.3737 Fax: 888.534.6531 October 20, 2016 Jonathan Cotliar, M.D. Re: Offer of Employment Dear Jonathan, On behalf of Science 37, Inc. (?Science 37?), I am pleased to offer you employment in the position of Vice President of Medical Affairs, reporting to Belinda Tan, M.D., Ph.D., Chief Medical Officer. Your respons |
|
| July 28, 2021 |
Consent of Bhooshi DeSilva to be named as a director. Exhibit 99.5 Consent to be Named as a Director Nominee In connection with the filing by LifeSci Acquisition II Corp. of the Registration Statement on Form S-4 (the ?Registration Statement?) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the |
|
| July 28, 2021 |
Offer Letter by and between Science 37, Inc. and David Coman, dated November 13, 2019. Exhibit 10.15 David Coman November 13, 2019 12121 Bluff Creek Drive, Suite 100 Los Angeles, CA 90094 Phone: 984.377.3737 Fax: 888.534.6531 November 13, 2019 David Coman Re: Offer of Employment Dear David, On behalf of Science 37, Inc. ("Science 37"), I am pleased to offer you employment in the position of Chief Executive Officer, reporting to Science 37's Board of Directors (the "Board of Director |
|
| July 27, 2021 |
Giovanni Caruso Partner 345 Park Avenue New York, NY 10154 Direct?????212.407.4866 Main???????212.407.4000 Fax??????????212.937.3943 [email protected] Via Edgar July 27, 2021 Scott Anderegg Jennifer L?pez-Molina Division of Corporation Finance Office of Trade & Services U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Lifesci Acquisition II Corp. Draft Registrat |
